[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100364916":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":36,"locations":44,"responsibleParty":65,"collaborators":67,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":27,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":35,"studyType":84,"phases":85,"briefSummary":88,"conditions":89,"keywords":35,"overallStatus":47,"whyStopped":35,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Genesis Athens Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants receiving PRP treatment","EXPERIMENTAL","Women presenting with POI, 25-39 years of age, treated with autologous PRP intra ovarian infusion",[13],"Biological: Autologous Platelet Rich Plasma",{"label":15,"type":16,"description":17,"interventionNames":18},"Participants receiving Platelet Free Plasma (PFP) treatment","PLACEBO_COMPARATOR","Women presenting with POI, 25-39 years of age, treated with autologous PFP intra ovarian infusion",[19],"Biological: Placebo-Platelet Free Plasma",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BIOLOGICAL","Autologous Platelet Rich Plasma","Autologous PRP intra ovarian infusion",[9],[27,28],"PRP","Platelet Rich Plasma",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Placebo-Platelet Free Plasma","Autologous PFP intra ovarian infusion",[15],[34],"PFP",null,[37,42],{"name":38,"role":39,"phone":40,"phoneExt":35,"email":41},"Mara Simopoulou, PhD","CONTACT","+306979234100","marasimopoulou@hotmail.com",{"name":43,"role":39,"phone":35,"phoneExt":35,"email":35},"Agni Pantou, MD, PhD Candidate",[45],{"facility":46,"status":47,"city":48,"state":35,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Genesis AC","RECRUITING","Athens","15232","Greece","GR",{"type":53,"coordinates":54},"Point",[55,56],23.72784,37.98376,{"lat":56,"lon":55},[59,60,63],{"name":38,"role":39,"phone":35,"phoneExt":35,"email":35},{"name":61,"role":62,"phone":35,"phoneExt":35,"email":35},"Agni Pantou, MD","PRINCIPAL_INVESTIGATOR",{"name":64,"role":62,"phone":35,"phoneExt":35,"email":35},"Konstantinos Pantos, MD, PhD",{"type":66,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR",[68],{"name":69,"class":6},"National and Kapodistrian University of Athens","100364916","phase-2-autologous-prp-infusion-may-restore-ovarian-function-and-may-promote-folliculogenesis-in-poi-patients-100364916",false,"NCT04031456","Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients","Investigating Reactivation of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in POI Patients","Inclusion Criteria:\n\n* Age \\\u003C 40 years, presenting with amenorrhea or menstrual cycle irregularities for at least four months, and elevated FSH levels \\>25 IU\u002FL recorded on two occasions \\>4 weeks apart\n* Normal Karyotype: 46, XX\n* Discontinuation of any complementary\u002Fadjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment.\n* Willing to comply with study requirements\n\nExclusion Criteria:\n\n* Any pathological disorder related to reproductive system anatomy\n* AMH \\> 8 pmol\u002FL\n* Endometriosis\n* Adenomyosis\n* Fibroids and adhesions\n* Infections in reproductive system\n* Current or previous diagnosis of cancer in reproductive system\n* History of familiar cancer in reproductive system\n* Severe male factor infertility\n* Prior referral for PGT\n* Ovarian inaccessibility\n* Endocrinological disorders (Hypothalamus-Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)\n* BMI\\>30 kg\u002Fm2 or BMI\\\u003C18.5 kg\u002Fm2\n* Systematic autoimmune disorders",true,"FEMALE","25 Years","39 Years",{"count":82,"type":83},100,"ESTIMATED","INTERVENTIONAL",[86,87],"PHASE2","PHASE3","Autologous PRP intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve patients' hormonal profile in patients presenting with POI.",[90,91,92,93,94],"Menopause, Premature","Menopause Related Conditions","Menopausal Syndrome","Premature Ovarian Failure","Ovarian Failure, Premature","2024-12-20",{"date":97,"type":98},"2024-12-24","ACTUAL",{"date":100,"type":98},"2019-07-30",{"date":102,"type":83},"2026-07-30",{"name":5,"class":6},1]